|
US3133858A
(en)
*
|
1954-03-24 |
1964-05-19 |
Abbott Lab |
Stable thiobarbituric acid solution
|
|
CH527207A
(de)
|
1968-05-08 |
1972-08-31 |
Ceskoslovenska Akademie Ved |
Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
|
|
DE2105468A1
(en)
|
1970-04-23 |
1971-11-18 |
Czeskoslovenska akademie ved, Prag; VtnKarstedt, E., Dipl.-Ing. Dr., Pat-Anw., 4200 Oberhausen |
1-glycosyl-5-aza-cytosines prepn
|
|
US5157120A
(en)
|
1980-09-16 |
1992-10-20 |
Syntex (U.S.A.) Inc. |
Guanine derivatives
|
|
US4855304A
(en)
|
1985-01-10 |
1989-08-08 |
Repligen Corporation |
Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
|
|
JPS61176523A
(ja)
|
1985-01-30 |
1986-08-08 |
Teruhiko Beppu |
制癌剤
|
|
GB8612826D0
(en)
|
1986-05-27 |
1986-07-02 |
Boots Co Plc |
Insecticidal compositions
|
|
DE3712786A1
(de)
|
1987-04-15 |
1988-11-03 |
Merck Patent Gmbh |
Verfahren und mittel zur bestimmung von nucleinsaeuren
|
|
CS269077B1
(cs)
|
1987-10-01 |
1990-04-11 |
Piskala Alois |
Způsob přípravy 5-azacytosinů
|
|
US5968914A
(en)
|
1987-10-28 |
1999-10-19 |
Pro-Neuron, Inc. |
Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
|
|
US5736531A
(en)
|
1987-10-28 |
1998-04-07 |
Pro-Neuron, Inc. |
Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
|
|
US4904770A
(en)
|
1988-03-24 |
1990-02-27 |
Bristol-Myers Company |
Production of 2',3'-dideoxy-2',3'-didehydronucleosides
|
|
US5324831A
(en)
|
1988-04-06 |
1994-06-28 |
The United States Of America As Represented By The Secretary Of Health And Human Services |
Phosphoramidite reagent for chemical synthesis of modified DNA
|
|
PT93772A
(pt)
|
1989-04-17 |
1991-01-08 |
Searle & Co |
Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
|
|
ZA923640B
(en)
|
1991-05-21 |
1993-02-24 |
Iaf Biochem Int |
Processes for the diastereoselective synthesis of nucleosides
|
|
CA2111571C
(en)
|
1991-07-05 |
2005-08-23 |
Reid W. Von Borstel |
Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
|
|
IL103311A0
(en)
|
1991-10-07 |
1993-03-15 |
Univ Johns Hopkins |
Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
|
|
JPH05219974A
(ja)
|
1992-02-13 |
1993-08-31 |
Mitsui Petrochem Ind Ltd |
トロパンアルカロイドの製造方法
|
|
JPH05246891A
(ja)
*
|
1992-03-09 |
1993-09-24 |
Kobayashi Seiyaku Kogyo Kk |
安定な抗膵炎用注射液
|
|
US5607691A
(en)
|
1992-06-12 |
1997-03-04 |
Affymax Technologies N.V. |
Compositions and methods for enhanced drug delivery
|
|
AU6081294A
(en)
|
1993-05-14 |
1994-12-12 |
Pro-Neuron, Inc. |
Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
|
|
GB9311252D0
(en)
|
1993-06-01 |
1993-07-21 |
Hafslund Nycomed As |
Cell growth regualtors
|
|
KR100392057B1
(ko)
|
1993-11-30 |
2003-10-30 |
맥길 유니버시티 |
세포의 CpG 디뉴클레오티드 내의 시토신의 메틸화를 감소하는 방법
|
|
US6432924B1
(en)
|
1993-12-26 |
2002-08-13 |
East Carolina University |
Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
|
|
US5856090A
(en)
|
1994-09-09 |
1999-01-05 |
The Scripps Research Institute |
DNA-methylase linking reaction
|
|
US20030104576A1
(en)
|
1994-10-07 |
2003-06-05 |
Jonathan W. Nyce |
Dna construct, composition, formulations & methods for making the construct & for modulating expression
|
|
WO1996036693A1
(en)
|
1995-05-19 |
1996-11-21 |
Phytera, Inc. |
Manipulation of plant cell and tissue cultures
|
|
JPH11507047A
(ja)
|
1995-06-06 |
1999-06-22 |
ケース ウエスターン リザーブ ユニバーシティ |
ヒト間葉幹細胞の筋原性分化
|
|
RU98113785A
(ru)
|
1995-12-22 |
2000-06-10 |
Ист Каролина Юниверсити (US) |
Агент и способ лечения заболеваний, связанных с чрезмерной экспрессией цитидиндезаминазы или дезоксицитидинзаминазы
|
|
CN1268140A
(zh)
|
1996-10-16 |
2000-09-27 |
Icn药品公司 |
单环l－核苷、类似物及其应用
|
|
US6423692B2
(en)
|
1997-04-24 |
2002-07-23 |
Dana-Farber Cancer Institute, Inc. |
Method of enhancing the effectiveness of DCK phosphorylated molecules
|
|
US6153383A
(en)
|
1997-12-09 |
2000-11-28 |
Verdine; Gregory L. |
Synthetic transcriptional modulators and uses thereof
|
|
TR200002284T2
(tr)
|
1998-02-05 |
2000-11-21 |
Smithkline Beecham Biologicals S.A. |
Mage ailesinden tümör ile ilgili tümör türevleri
|
|
WO2000023112A1
(en)
|
1998-10-19 |
2000-04-27 |
Methylgene, Inc. |
Modulation of gene expression by combination therapy
|
|
DK2112166T3
(en)
|
1998-12-23 |
2019-02-04 |
Pfizer |
Human monoclonal antibodies to CTLA-4
|
|
WO2000040269A2
(en)
|
1999-01-05 |
2000-07-13 |
Lee Clarence C |
Pharmaceutical compositions for treatment of diseased tissues
|
|
WO2000062075A1
(en)
|
1999-04-13 |
2000-10-19 |
Rutgers, The State University Of New Jersey |
Ubiquitin cross-reactive protein as a prognostic marker for tumor cell chemosensitivity
|
|
WO2000074634A2
(en)
|
1999-06-03 |
2000-12-14 |
Au Jessie L S |
Methods and compositions for modulating cell proliferation and cell death
|
|
DE19935303A1
(de)
|
1999-07-28 |
2001-02-08 |
Aventis Pharma Gmbh |
Oligonukleotide zur Inhibierung der Expression von humanem eg5
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
JP2001163776A
(ja)
*
|
1999-09-30 |
2001-06-19 |
Nisshin Oil Mills Ltd:The |
安定化された液剤
|
|
AU785115B2
(en)
|
1999-10-18 |
2006-09-21 |
Emory University |
TMS1 compositions and methods of use
|
|
US20020115117A1
(en)
|
2000-03-15 |
2002-08-22 |
Shuk-Mei Ho |
ERbeta-mediated gene expression
|
|
EP1315970B1
(en)
|
2000-09-08 |
2010-03-17 |
Seoul National University Industry Foundation |
Nucleic acid sequence and protein involved in cellular senescence
|
|
US6919370B2
(en)
*
|
2000-11-28 |
2005-07-19 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
|
|
WO2002053138A2
(en)
|
2001-01-02 |
2002-07-11 |
Elisabeth Shanahan-Prendergast |
Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
|
|
DZ3487A1
(fr)
|
2001-01-22 |
2002-07-25 |
Merck Sharp & Dohme |
Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
|
|
JP2002223753A
(ja)
|
2001-01-30 |
2002-08-13 |
Hitachi Ltd |
薬物応答解析用オリゴヌクレオチドアレイ
|
|
ES2252461T3
(es)
|
2001-02-05 |
2006-05-16 |
Innoventus Project Ab |
Glicoproteina rica en histidina (hrgp) para la inhibicion de la angiogenesis.
|
|
US6613753B2
(en)
|
2001-02-21 |
2003-09-02 |
Supergen, Inc. |
Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
|
|
WO2002069903A2
(en)
|
2001-03-06 |
2002-09-12 |
Biocryst Pharmaceuticals, Inc. |
Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
|
|
US20060194275A1
(en)
|
2001-04-13 |
2006-08-31 |
Incyte Corporation |
Transporter and ion channels
|
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
|
EP2283845A1
(en)
|
2001-04-26 |
2011-02-16 |
pSivida Inc. |
Sustained release drug delivery system containing codrugs
|
|
US20030148973A1
(en)
|
2001-05-23 |
2003-08-07 |
Peter Emtage |
MAGE-A1 peptides for treating or preventing cancer
|
|
JP2004536596A
(ja)
|
2001-06-08 |
2004-12-09 |
ユー．エス． ジェノミクス， インコーポレイテッド |
メチル化状態に基づいて核酸を分析するための方法および生成物
|
|
JP2002370939A
(ja)
|
2001-06-12 |
2002-12-24 |
Taisho Pharmaceut Co Ltd |
育毛剤
|
|
US20030045497A1
(en)
|
2001-07-27 |
2003-03-06 |
Geneinvent Bbl Ab |
Methylation resistant vectors
|
|
SE518759C2
(sv)
|
2001-07-27 |
2002-11-19 |
Geneinvent Bbl Ab |
Vektorer motståndskraftiga mot metylering
|
|
WO2003012085A1
(en)
|
2001-07-30 |
2003-02-13 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Antigen presenting cells, method for their preparation and their use for cancer vaccines
|
|
ES2334774T3
(es)
|
2001-09-05 |
2010-03-16 |
Chemgenex Pharmaceuticals Limited |
Tratamiento de la leucemia mielogena cronica, resistente o intoleranteal sti571, que consiste en homoharrigtonina sola o combinada con otros agentes.
|
|
IN2014DN10834A
(enExample)
|
2001-09-17 |
2015-09-04 |
Psivida Inc |
|
|
US20030158598A1
(en)
|
2001-09-17 |
2003-08-21 |
Control Delivery Systems, Inc. |
System for sustained-release delivery of anti-inflammatory agents from a coated medical device
|
|
CN100441176C
(zh)
|
2001-09-24 |
2008-12-10 |
杰西·L·S·奥 |
测定联合疗法中使用的苏拉明的化学敏感化剂量的方法和组合物
|
|
WO2003031932A2
(en)
|
2001-10-05 |
2003-04-17 |
Case Western Reserve University |
Methods and compositions for detecting colon cancers
|
|
KR100616369B1
(ko)
|
2001-11-08 |
2006-08-28 |
도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 |
벼의 트랜스포존 유전자
|
|
MXPA04004882A
(es)
|
2001-11-23 |
2005-04-11 |
Chugai Pharmaceutical Co Ltd |
Metodo para la identificacion de enzimas que tienen como objetivo tumores.
|
|
RU2313365C2
(ru)
|
2001-11-29 |
2007-12-27 |
Дандрит Байотек А/С |
Фармацевтическая композиция для индукции иммунной реакции у человека
|
|
US20050080027A1
(en)
|
2001-11-30 |
2005-04-14 |
Markus Horer |
Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors
|
|
GB0201498D0
(en)
|
2002-01-23 |
2002-03-13 |
Biotech Res Ventures Pte Ltd |
Materials and methods for treating cancer
|
|
US20030147813A1
(en)
|
2002-02-07 |
2003-08-07 |
John Lyons |
Method for treating chronic myelogenous leukemia
|
|
US6998391B2
(en)
|
2002-02-07 |
2006-02-14 |
Supergen.Inc. |
Method for treating diseases associated with abnormal kinase activity
|
|
WO2003076660A1
(en)
|
2002-03-13 |
2003-09-18 |
F.Hoffmann-La Roche Ag |
Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
|
|
JP2003310293A
(ja)
|
2002-04-26 |
2003-11-05 |
Mitsui Chemicals Inc |
ヌクレオシド化合物の製造法
|
|
DK1507556T3
(en)
|
2002-05-02 |
2016-09-12 |
Wyeth Holdings Llc |
Calicheamicin derivative-carrier conjugates
|
|
AU2003251483A1
(en)
|
2002-06-05 |
2003-12-22 |
Case Western Reserve University |
Methods and compositions for detecting cancers
|
|
US6982253B2
(en)
|
2002-06-05 |
2006-01-03 |
Supergen, Inc. |
Liquid formulation of decitabine and use of the same
|
|
EP1556010A4
(en)
|
2002-10-31 |
2007-12-05 |
Supergen Inc |
PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
|
|
US20050037992A1
(en)
|
2003-07-22 |
2005-02-17 |
John Lyons |
Composition and method for treating neurological disorders
|
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
|
WO2005033278A2
(en)
|
2003-09-30 |
2005-04-14 |
Ludwig Institute For Cancer Research |
In vivo efficacy of ny-eso-1 plus iscom
|
|
US7846436B2
(en)
|
2003-11-28 |
2010-12-07 |
Chemgenes Corporation |
Oligonucleotides and related compounds
|
|
WO2005115450A1
(en)
|
2004-05-26 |
2005-12-08 |
Biovaxim Limited |
Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same
|
|
US20060014949A1
(en)
|
2004-07-13 |
2006-01-19 |
Supergen Inc. |
Compositions and formulations of decitabine polymorphs and methods of use thereof
|
|
US20060069060A1
(en)
|
2004-09-27 |
2006-03-30 |
Sanjeev Redkar |
Salts of decitabine
|
|
US20060063735A1
(en)
|
2004-09-17 |
2006-03-23 |
Supergen, Inc. |
Salts of 5-azacytidine
|
|
JP2008518902A
(ja)
|
2004-11-04 |
2008-06-05 |
ファイザー・プロダクツ・インク |
乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療
|
|
US20060128654A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
|
US20060128653A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of decitabine
|
|
EP1833506B1
(en)
|
2004-12-29 |
2015-08-26 |
Mannkind Corporation |
Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
|
|
US7250416B2
(en)
|
2005-03-11 |
2007-07-31 |
Supergen, Inc. |
Azacytosine analogs and derivatives
|
|
JO2787B1
(en)
*
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
US20070105792A1
(en)
|
2005-11-04 |
2007-05-10 |
Dimartino Jorge F |
Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
|
|
US20070117776A1
(en)
|
2005-11-04 |
2007-05-24 |
John Lyons |
Low Dose Therapy Of DNA Methylation Inhibitors
|
|
CN101637444B
(zh)
*
|
2006-03-17 |
2012-08-15 |
山东蓝金生物工程有限公司 |
含吉西他滨的抗癌药物缓释注射剂
|
|
US20090142337A1
(en)
*
|
2006-05-08 |
2009-06-04 |
Astex Therapeutics Limited |
Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
|
|
US8003324B2
(en)
*
|
2007-10-18 |
2011-08-23 |
U.S. Department Of Veterans Affairs |
Modulation of sodium channels by nicotinamide adenine dinucleotide
|
|
CN101570553B
(zh)
*
|
2008-05-04 |
2012-03-28 |
上海医药工业研究院 |
一种2-脱氧-d-核糖的衍生物及其制备方法和用途
|
|
CN101361718B
(zh)
*
|
2008-09-26 |
2013-08-28 |
深圳万乐药业有限公司 |
稳定的地西他滨冻干制剂的制备方法
|
|
CN101787046B
(zh)
*
|
2010-02-11 |
2012-12-26 |
福建南方制药股份有限公司 |
地西他滨的中间体化合物的制备方法
|
|
GB201006096D0
(en)
|
2010-04-13 |
2010-05-26 |
Alligator Bioscience Ab |
Novel compositions and uses thereof
|
|
JP6121904B2
(ja)
|
2010-09-08 |
2017-04-26 |
ハロザイム インコーポレイテッド |
条件的活性治療用タンパク質を評価および同定する、または発展させる方法
|
|
CN101966157B
(zh)
*
|
2010-10-14 |
2013-08-14 |
苏州特瑞药业有限公司 |
一种地西他滨缓释微球及其制备方法
|
|
KR20140029446A
(ko)
|
2011-04-15 |
2014-03-10 |
컴퓨젠 엘티디. |
면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
|
|
HUE042327T2
(hu)
|
2011-08-30 |
2019-06-28 |
Astex Pharmaceuticals Inc |
Decitabin-származék készítmények
|
|
EP2811984B1
(en)
|
2012-02-06 |
2015-08-26 |
Fresenius Kabi Oncology Limited |
Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
|
|
DK2961388T3
(da)
|
2013-03-01 |
2019-07-08 |
Astex Pharmaceuticals Inc |
Kombinationer af lægemidler
|
|
US10485764B2
(en)
|
2015-07-02 |
2019-11-26 |
Otsuka Pharmaceutical Co., Ltd. |
Lyophilized pharmaceutical compositions
|
|
CN111182908A
(zh)
|
2017-08-03 |
2020-05-19 |
大塚制药株式会社 |
药物化合物及其纯化方法
|